Director / PDMR Shareholding
EKF Diagnostics Holdings plc
(“EKF” or the “Company”)
Notification of transactions by Persons Discharging Managerial Responsibilities and persons closely associated with them.
EKF Diagnostics Holdings plc (AIM: EKF) announces that on 18 July 2016, the Company was notified that Harwood Capital LLP ("Harwood") acquired 9,000,000 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") as investment manager to North Atlantic Smaller Companies Investment Trust PLC ("NAIT"). Christopher Mills, the Company's Non-Executive Chairman, is a partner and Chief Investment Officer of Harwood and a director and shareholder in NAIT.
Following the above transaction, which was completed on 15 July 2016 at a price of 14.89 pence per share, NAIT's interest is now in 87,100,000 Ordinary Shares, representing 18.76% of the Company's issued share capital. The interests of Oryx International Growth Fund Limited ("Oryx", whose investment adviser is Harwood) remains as previously disclosed in 40,000,000 Ordinary Shares, representing 8.62% of the Company's issued share capital. Mr Mills is also a director and shareholder in Oryx.
The total indirect beneficial interest of Mr Mills is, following the above transaction, therefore now in 127,100,000 Ordinary Shares, representing 27.38% of the Company's issued share capital.
This notification is made in accordance with the requirements of the EU Market Abuse Regulation. Further details:
Initial notification / amendment: Initial
Ordinary Shares Identification Code: ISIN GB0031509804
Aggregated information: N/A
Place of the transaction: London Stock Exchange, AIM (XLON)